Martinez P, Ortiz De Lejarazu R, Padron VF, Eiros JM, Rodriguez Torres A; International Conference on AIDS.
Int Conf AIDS. 1998; 12: 1173 (abstract no. 60945).
Serv. Microbiologia, Hosp. Universitario, Valladolid, Spain.
OBJECTIVES: To evaluate a new automated screening test for the simultaneous detection of anti-HIV1 and anti-HIV2 as well as p24 antigen. DESIGN: Transversal study. METHODS: A total of 383 serum samples were obtained, 218 negative serum samples (16 laboral accident, 50 pregnant women, 100 blood donors, 40 multiple transfusion recipients, 12 weak reactivities by ELFA or Western blot) and 165 HIV serum samples (158 positive serum and 7 BBI panel). Serum samples were tested using the VIDAS HIV DUO test (bioMerieux, France). This technique associates a final fluorescence reading (ELFA), which is automated in the VIDAS system. The disposable single-use cone serves both as a solid support (the lower section is coated with synthetic peptides representing the immunodominant region of GP41 for HIV1 and GP36 for HIV2, and the upper section is coated with anti-p24 monoclonal antibodies) and as a pipette system. The other reagents are arranged in ready-to-use cartridges having various recessed cups where the different reaction phases occur. The sample volume required is 200 microliters; the test time is 90 minutes. This test provides concentration values directly related to the fluorescence (Relative Fluorescent Value) detected in the reading. The gold standar for antibodies and p24 antigen were the Western blot (Bioblot HIV-1 plus, Genelabs Diagnostic, Switzerland) and ELAVIA Ag I (Sanofi Diagnostic Pasteur, France) respectively. RESULTS: The sensitivity and specificity were 100% and 96.8%. In the cases of recent infection, p24 antigen was detected at the same time by the test and the gold standard. The p24 antigen sensitivity was established at approximately 13 pgr/ml when tested with antigen standar (HIV-1 Antigen, Sanofi Diagnostics Pasteur, France). CONCLUSIONS: This test has proven with sufficient reliability (Sen: 100% and Spec: 96.8%) that it can be applied in the safety screening required for biological samples, and that it also allows the diagnosis of persons infected with HIV to be shortened in cases of acute infection, thanks to its ability to detect p24 antigen.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Antibodies
- Antigens
- Blotting, Western
- Evaluation Studies
- Female
- France
- HIV Antibodies
- HIV Antigens
- HIV Core Protein p24
- HIV Envelope Protein gp41
- HIV Infections
- HIV Seropositivity
- HIV-1
- HIV-2
- Humans
- Indicators and Reagents
- Pregnancy
- Reagent Kits, Diagnostic
- Research Design
- Switzerland
- immunology
- methods
- organization & administration
Other ID:
UI: 102232889
From Meeting Abstracts